{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T19:40:01Z","timestamp":1767901201572,"version":"3.49.0"},"reference-count":46,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2013,10,6]],"date-time":"2013-10-06T00:00:00Z","timestamp":1381017600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,10,6]]},"abstract":"<jats:title>Summary<\/jats:title>\n               <jats:p>Five patients with active disseminated vitiligo were given 1\u2009g of a chimeric (murine\/human) monoclonal antibody to CD20 in a single intravenous infusion and followed-up for 6 months. Three of the patients showed an overt clinical and histological improvement of the disease, one presented slight improvement and the remaining patient showed no changes. Improvement was neither associated with changes in laboratory parameters nor to a specific human leucocyte antigen D-related (HLA-DR) phenotype. We believe that these preliminary results are encouraging, and further clinical trials should be undertaken. An important aim should be the finding of a marker with a good response to this therapeutic approach.<\/jats:p>","DOI":"10.1111\/cei.12168","type":"journal-article","created":{"date-parts":[[2013,7,2]],"date-time":"2013-07-02T11:25:10Z","timestamp":1372764310000},"page":"229-236","source":"Crossref","is-referenced-by-count":24,"title":["Treatment of vitiligo with a chimeric monoclonal antibody to CD20: a pilot study"],"prefix":"10.1093","volume":"174","author":[{"given":"A","family":"Ruiz-Arg\u00fcelles","sequence":"first","affiliation":[{"name":"Laboratorios Cl\u00ednicos de Puebla, Puebla, Mexico"},{"name":"Universidad Popular Aut\u00f3noma del Estado de Puebla, Puebla, Mexico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Garc\u00eda-Carrasco","sequence":"additional","affiliation":[{"name":"Unidad de Investigaci\u00f3n de Enfermedades Autoinmunes Sist\u00e9micas, Instituto Mexicano del Seguro Social, Puebla, Mexico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G","family":"Jimenez-Brito","sequence":"additional","affiliation":[{"name":"Colegio de Dermatolog\u00eda de Puebla, Puebla, Mexico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S","family":"S\u00e1nchez-Sosa","sequence":"additional","affiliation":[{"name":"Universidad Popular Aut\u00f3noma del Estado de Puebla, Puebla, Mexico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B","family":"P\u00e9rez-Romano","sequence":"additional","affiliation":[{"name":"Laboratorios Cl\u00ednicos de Puebla, Puebla, Mexico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Garc\u00e9s-Eisele","sequence":"additional","affiliation":[{"name":"Laboratorios Cl\u00ednicos de Puebla, Puebla, Mexico"},{"name":"Universidad Popular Aut\u00f3noma del Estado de Puebla, Puebla, Mexico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C","family":"Camacho-Alarc\u00f3n","sequence":"additional","affiliation":[{"name":"Laboratorios Cl\u00ednicos de Puebla, Puebla, Mexico"},{"name":"Universidad Popular Aut\u00f3noma del Estado de Puebla, Puebla, Mexico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V","family":"Reyes-N\u00fa\u00f1ez","sequence":"additional","affiliation":[{"name":"Laboratorios Cl\u00ednicos de Puebla, Puebla, Mexico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Sandoval-Cruz","sequence":"additional","affiliation":[{"name":"Hospital General Regional 36 Centro M\u00e9dico Nacional, Instituto Mexicano del Seguro Social, Puebla, Mexico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C","family":"Mendoza-Pinto","sequence":"additional","affiliation":[{"name":"Unidad de Investigaci\u00f3n de Enfermedades Autoinmunes Sist\u00e9micas, Instituto Mexicano del Seguro Social, Puebla, Mexico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"L\u00f3pez-Colombo","sequence":"additional","affiliation":[{"name":"Hospital General Regional 36 Centro M\u00e9dico Nacional, Instituto Mexicano del Seguro Social, Puebla, Mexico"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2013,10,6]]},"reference":[{"key":"2021122009590258000_cei12168-bib-0001","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/S0190-9622(98)70194-X","article-title":"Vitiligo","volume":"38","author":"Kovacs","year":"1998","journal-title":"J Am Acad Dermatol"},{"key":"2021122009590258000_cei12168-bib-0002","first-page":"493","article-title":"Response to cosmetic disfigurement: patients with vitiligo","volume":"39","author":"Porter","year":"1987","journal-title":"Cutis"},{"key":"2021122009590258000_cei12168-bib-0003","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/0163-8343(79)90081-1","article-title":"Psychological reaction to chronic skin disorders: a study of patients with vitiligo","volume":"1","author":"Porter","year":"1979","journal-title":"Gen Hosp Psychiatry"},{"key":"2021122009590258000_cei12168-bib-0004","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1038\/labinvest.3780318","article-title":"Autoimmune melanocyte destruction in vitiligo","volume":"81","author":"Van den Wijngaard","year":"2001","journal-title":"Lab Invest"},{"key":"2021122009590258000_cei12168-bib-0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1017\/S1462399401003362","article-title":"Immunological pathomechanisms in vitiligo","volume":"3","author":"Kemp","year":"2001","journal-title":"Exp Rev Mol Med"},{"key":"2021122009590258000_cei12168-bib-0006","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S0065-2776(06)90006-6","article-title":"Unraveling the complex relationship between cancer immunity and autoimmunity: lessons from melanoma and vitiligo","volume":"90","author":"Uchi","year":"2006","journal-title":"Adv Immunol"},{"key":"2021122009590258000_cei12168-bib-0007","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1016\/S0190-9622(87)70119-4","article-title":"Childhood vitiligo","volume":"16","author":"Halder","year":"1987","journal-title":"J Am Acad Dermatol"},{"key":"2021122009590258000_cei12168-bib-0008","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/S0733-8635(18)30328-0","article-title":"Ocular manifestations of pigmentary disorders","volume":"10","author":"Park","year":"1992","journal-title":"Dermatol Clin"},{"key":"2021122009590258000_cei12168-bib-0009","doi-asserted-by":"crossref","first-page":"935","DOI":"10.7326\/0003-4819-71-5-935","article-title":"Vitiligo in Graves' disease","volume":"71","author":"Ochi","year":"1969","journal-title":"Ann Intern Med"},{"key":"2021122009590258000_cei12168-bib-0010","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1111\/j.1365-2133.1985.tb02057.x","article-title":"Vitiligo in diabetes mellitus","volume":"113","author":"Gould","year":"1985","journal-title":"Br J Dermatol"},{"key":"2021122009590258000_cei12168-bib-0011","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1002\/bies.950180507","article-title":"Molecular mechanisms of anti-inflammatory action of glucocorticoids","volume":"18","author":"Cato","year":"1996","journal-title":"Bioessays"},{"key":"2021122009590258000_cei12168-bib-0012","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1084\/jem.189.8.1285","article-title":"A critical role for Fas ligand in the active suppression of systemic immune responses by ultraviolet radiation","volume":"189","author":"Hill","year":"1999","journal-title":"J Exp Med"},{"key":"2021122009590258000_cei12168-bib-0013","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/S0140-6736(94)91709-4","article-title":"The role of tyrosine in autoinmune vitiligo","volume":"344","author":"Song","year":"1994","journal-title":"Lancet"},{"key":"2021122009590258000_cei12168-bib-0014","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.sder.2009.04.008","article-title":"Vitiligo update","volume":"28","author":"Halder","year":"2009","journal-title":"Semin Cutan Med Surg"},{"key":"2021122009590258000_cei12168-bib-0015","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.autrev.2010.02.013","article-title":"Current remedies for vitiligo","volume":"9","author":"Abu Tahir","year":"2010","journal-title":"Autoimmun Rev"},{"key":"2021122009590258000_cei12168-bib-0016","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1111\/1523-1747.ep12324456","article-title":"In vivo destruction of melanocytes by the IgG fraction of serum from patients with vitiligo","volume":"105","author":"Gulhar","year":"1995","journal-title":"J Invest Dermatol"},{"key":"2021122009590258000_cei12168-bib-0017","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.jaut.2007.07.012","article-title":"Apoptosis of melanocytes in vitiligo results from antibody penetration","volume":"29","author":"Ruiz-Arg\u00fcelles","year":"2007","journal-title":"J Autoimmun"},{"key":"2021122009590258000_cei12168-bib-0018","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/j.autrev.2011.02.004","article-title":"Immunopathogenesis of vitiligo","volume":"10","author":"Sandoval-Cruz","year":"2011","journal-title":"Autoimmun Rev"},{"key":"2021122009590258000_cei12168-bib-0019","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1111\/cei.12096","article-title":"Immunophenotypic characterization of lymphoid cell infiltrates in vitiligo","volume":"173","author":"S\u00e1nchez-Sosa","year":"2013","journal-title":"Clin Exp Immunol"},{"key":"2021122009590258000_cei12168-bib-0020","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1136\/pmj.78.924.599","article-title":"Current concepts for the management of systemic lupus erythematosus in adults: a therapeutic challenge","volume":"78","author":"Ioannou","year":"2002","journal-title":"Postgrad Med J"},{"key":"2021122009590258000_cei12168-bib-0021","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/ncprheum0042","article-title":"B-cell targeted therapies in rheumatoid arthritis and systemic lupus erythematosus","volume":"2","author":"Eisenberg","year":"2006","journal-title":"Nat Clin Pract Rheumatol"},{"key":"2021122009590258000_cei12168-bib-0022","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1038\/ni0901-764","article-title":"Systemic lupus erythematosus: an autoimmune disease of B cell hyperactivity","volume":"2","author":"Lipsky","year":"2001","journal-title":"Nat Immunol"},{"key":"2021122009590258000_cei12168-bib-0023","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.2165\/00003495-200666150-00004","article-title":"B-cell-targeted therapy for systemic lupus erythematosus","volume":"66","author":"Sabahi","year":"2006","journal-title":"Drugs"},{"key":"2021122009590258000_cei12168-bib-0024","doi-asserted-by":"crossref","first-page":"2580","DOI":"10.1002\/art.20430","article-title":"B cell depletion as a novel treatment of systemic lupus erythematosus: a phase I\/II dose-escalation trial of rituximab","volume":"50","author":"Looney","year":"2004","journal-title":"Arthritis Rheum"},{"key":"2021122009590258000_cei12168-bib-0025","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1093\/rheumatology\/kei080","article-title":"B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients","volume":"44","author":"Leandro","year":"2005","journal-title":"Rheumatology (Oxf)"},{"key":"2021122009590258000_cei12168-bib-0026","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1136\/ard.2006.067124","article-title":"B cell depletion therapy in systemic lupus erythematosus: long-term follow-up and predictors of response","volume":"66","author":"Ng","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"2021122009590258000_cei12168-bib-0027","doi-asserted-by":"crossref","first-page":"2970","DOI":"10.1002\/art.22046","article-title":"Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis","volume":"54","author":"Smith","year":"2006","journal-title":"Arthritis Rheum"},{"key":"2021122009590258000_cei12168-bib-0028","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1002\/art.22629","article-title":"Six refractory lupus patients treated with rituximab: a cases series","volume":"57","author":"Gillis","year":"2007","journal-title":"Arthritis Rheum"},{"key":"2021122009590258000_cei12168-bib-0029","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1002\/art.22505","article-title":"Histopathologic and clinical outcome of rituximab treatment in patients with cyclophosphamide-resistant proliferative lupus nephritis","volume":"56","author":"Gunnarsson","year":"2007","journal-title":"Arthritis Rheum"},{"key":"2021122009590258000_cei12168-bib-0030","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1002\/art.20858","article-title":"Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T-cell costimulatory molecule CD40 ligand: an open label trial","volume":"52","author":"Sfikakis","year":"2005","journal-title":"Arthritis Rheum"},{"key":"2021122009590258000_cei12168-bib-0031","doi-asserted-by":"crossref","first-page":"R83","DOI":"10.1186\/ar1954","article-title":"Clinical and immunological effects of Rituximab in patients with lupus nephritis refractory to convencional therapy: a pilot study","volume":"8","author":"Vigna-Perez","year":"2006","journal-title":"Arthritis Res Ther"},{"key":"2021122009590258000_cei12168-bib-0032","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1136\/ard.2006.057885","article-title":"Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving central nervous systemic","volume":"66","author":"Tokunaga","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"2021122009590258000_cei12168-bib-0033","first-page":"465","article-title":"Severe burns; therapy, homografts","volume":"26","author":"Kirschbaum","year":"1954","journal-title":"Dia Med"},{"key":"2021122009590258000_cei12168-bib-0034","doi-asserted-by":"publisher","first-page":"pdb.prot4820","DOI":"10.1101\/pdb.prot4820","article-title":"Immunohistochemistry of whole-mount mouse embryos","volume":"2008","author":"Joyner","year":"2008","journal-title":"CSH Protoc"},{"key":"2021122009590258000_cei12168-bib-0035","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S0300-483X(96)03600-1","article-title":"Immunohistochemistry for light microscopy in safety evaluation of therapeutic agents: an overview","volume":"119","author":"Burnett","year":"1997","journal-title":"Toxicology"},{"key":"2021122009590258000_cei12168-bib-0036","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1354\/vp.42-4-405","article-title":"Technical aspects of immunohistochemistry","volume":"42","author":"Ramos-Vara","year":"2005","journal-title":"Vet Pathol"},{"key":"2021122009590258000_cei12168-bib-0037","article-title":"Serum antibodies to melanocytes in patients with vitiligo are predictors of disease progression","author":"Jim\u00e9nez-Brito","year":"2013","journal-title":"Skinmed"},{"key":"2021122009590258000_cei12168-bib-0038","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1258\/000456307782268237","article-title":"Evaluation of immunoturbidimetric specific protein methods using the Architect ci8200: comparison with immunonephelometry","volume":"44","author":"Denham","year":"2007","journal-title":"Ann Clin Biochem"},{"key":"2021122009590258000_cei12168-bib-0039","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/0009-9120(95)02017-9","article-title":"General concepts about cell sorting techniques","volume":"29","author":"Orfao","year":"1996","journal-title":"Clin Biochem"},{"key":"2021122009590258000_cei12168-bib-0040","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1016\/0009-8981(92)90200-A","article-title":"Flow cytometry in the clinical laboratory. Principles, applications and problems","volume":"211","author":"Ruiz-Arg\u00fcelles","year":"1992","journal-title":"Clin Chim Acta"},{"key":"2021122009590258000_cei12168-bib-0041","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.jaad.2004.07.005","article-title":"HLA-DRB1*04 is associated with the genetic susceptibility to develop vitiligo in Mexican patients with autoimmune thyroid disease","volume":"52","author":"Orozco-Topete","year":"2005","journal-title":"J Am Acad Dermatol"},{"key":"2021122009590258000_cei12168-bib-0042","first-page":"9","article-title":"PCR\u2013RFLP","volume-title":"Handbook of HLA typing techniques","author":"Inoko","year":"1993"},{"key":"2021122009590258000_cei12168-bib-0043","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1586\/erp.09.23","article-title":"Burden of skin diseases","volume":"9","author":"Basra","year":"2009","journal-title":"Exp Rev Pharmacoecon Outcomes Res"},{"key":"2021122009590258000_cei12168-bib-0044","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1159\/000246657","article-title":"Investigation of the personality structure in patients with vitiligo and a possible association with impaired catecholamine metabolism","volume":"190","author":"Salzer","year":"1995","journal-title":"Dermatology"},{"key":"2021122009590258000_cei12168-bib-0045","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/S0190-9622(86)70160-6","article-title":"Psychosocial effect of vitiligo: a comparison of vitiligo patients with \u2018normal\u2019 control subjects, with psoriasis patients, and with patients with other pigmentary disorders","volume":"15","author":"Porter","year":"1986","journal-title":"J Am Acad Dermatol"},{"key":"2021122009590258000_cei12168-bib-0046","first-page":"19","article-title":"Frequency and pattern of psychiatric disorders in patients with vitiligo","volume":"19","author":"Ahmed","year":"2007","journal-title":"J Ayub Med Coll Abbottabad"}],"container-title":["Clinical and Experimental Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fcei.12168","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/cei\/article-pdf\/174\/2\/229\/41789027\/cei12168.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cei\/article-pdf\/174\/2\/229\/41789027\/cei12168.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T16:25:07Z","timestamp":1641054307000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cei\/article\/174\/2\/229\/6421011"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10,6]]},"references-count":46,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2013,10,6]]},"published-print":{"date-parts":[[2013,10,6]]}},"URL":"https:\/\/doi.org\/10.1111\/cei.12168","relation":{},"ISSN":["1365-2249","0009-9104"],"issn-type":[{"value":"1365-2249","type":"electronic"},{"value":"0009-9104","type":"print"}],"subject":[],"published-other":{"date-parts":[[2013,11]]},"published":{"date-parts":[[2013,10,6]]}}}